Skip to content

Biostatistician

Consult with clinical team on trial design

Enhances◐ 1–3 years

What You Do Today

Advise on endpoint selection, design trade-offs (parallel vs crossover, superiority vs non-inferiority), power implications of design choices

AI That Applies

AI simulates trial outcomes under different design options, quantifying trade-offs in power, cost, and timeline for each alternative

Technologies

How It Works

The system ingests clinical data — patient records, lab results, vitals, and care history from the EHR. A language model processes the input by identifying relevant context, generating appropriate responses, and structuring the output to match the expected format and domain conventions. The results integrate into the practitioner's existing workflow — presenting recommendations, flags, or automated outputs alongside their normal working context.

What Changes

You bring quantified trade-offs to design discussions instead of conceptual arguments; AI shows 'if we switch to crossover, power increases 12% but dropout risk rises'

What Stays

You provide the statistical judgment that balances scientific rigor with operational reality and regulatory expectations

What To Do Next

This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.

1

Establish Your Baseline

Know where you are before you move

Before adopting AI tools for consult with clinical team on trial design, understand your current state.

•
Map your current process: Document how consult with clinical team on trial design works today — who does what, how long it takes, where the bottlenecks are. You need this baseline to measure improvement.
•
Identify the judgment points: You provide the statistical judgment that balances scientific rigor with operational reality and regulatory expectations. These are the boundaries AI won't cross.
•
Assess your data readiness: AI tools for this area need data to work. Check whether your organization has the historical data, integrations, and data quality to support R Shiny tools.

Without a baseline, you can't measure whether AI actually improved anything. You'll adopt tools without knowing if they're working.

2

Define Your Measures

What to track and how to calculate it

Time per cycle

How to calculate

Measure how long consult with clinical team on trial design takes end-to-end today, then after AI adoption.

Why it matters

The most visible improvement is speed. If AI doesn't save time, question whether it's adding value.

Quality of output

How to calculate

Track error rates, rework frequency, or stakeholder satisfaction scores before and after.

Why it matters

Speed without quality is just faster mistakes. Measure both.

When to check: Check after 30 days of consistent use, then quarterly.
The commitment: Give new tools at least 30 days before judging. The first week is always awkward.
What NOT to measure: Don't measure AI adoption rate as a KPI. Adoption follows value — if the tool helps, people use it.
3

Start These Conversations

Who to talk to and what to ask

your data engineering lead

“What data do we already have that could improve how we handle consult with clinical team on trial design?”

They control the data pipelines that feed your analysis

your VP or director of analytics

“Who on our team has the deepest experience with consult with clinical team on trial design, and what tools are they already using?”

They're deciding the team's AI tool adoption strategy

your data governance lead

“If we brought in AI tools for consult with clinical team on trial design, what would we measure before and after to know it actually helped?”

AI-generated insights need the same quality standards as manual analysis

4

Check Your Prerequisites

Confirm readiness before you invest

Check items as you confirm them.

← Back to AI for Biostatisticians